Related Experiment Video
Updated: May 9, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Safe and Efficacious Use of Low-Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia
Jennifer Darlow1, Gerard Gurumurthy2, Nathan Jeffreys1
1Royal Manchester Children's Hospital Manchester UK.
Background:
Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m2 weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This study evaluates lower-dose Rituximab with dexamethasone in postpubertal pediatric ITP patients.
Methods:
Patients treated with 100 mg weekly Rituximab for 4 weeks alongside dexamethasone at 10 mg/m2 on days 1-5 and 21-25 were assessed for response and safety.
Results:
Of the 10 patients treated, six responded completely, one partially and three showed no response. Four responders maintained their response over 2 years. One Rituximab-related infusion reaction and one Dexamethasone-related adverse event were reported.
Conclusion:
Rituximab 100 mg weekly may be non-inferior to 375 mg/m2 weekly for paediatric patients.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
